Vorpal joins MCRA LLC

HekaBio is delighted to announce the merger of our subsidiary consultancy, Vorpal Technologies K.K. (https://www.vorpaltechnologies.com/), with MCRA LLC (https://www.mcra.com/). MCRA, headquartered in Washington, DC, is a leading regulatory, clinical and reimbursement consultancy and full-service CRO with three offices in the US, one office in Europe and now one in Tokyo.

Vorpal is the leader in Japan for new category MedTech shonin approvals, recently securing three approvals in a single week to close out a successful 2021. This merger enables Vorpal to accelerate expansion, meeting demand as the premier portal into Japan for worldwide MedTech innovations.

HekaBio will benefit from this transaction in several important ways. One is an ongoing strategic alliance with MCRA on a global level. Another is expanded bandwidth and sharpened focus on advancing our strategic in-house programs.

最新記事

すべて表示

We are very pleased to announce that we have completed treatment of all planned patients in our HB-001 open label study to test the safety and efficacy of the Alpha DaRT targeted alpha radiation thera